Compound: medroxyprogesterone
SMILES: O=C1C=C2[C@]([C@@H]3[C@H]([C@H]4[C@]([C@@](O)(C(=O)C)CC4)(C)CC3)C[C@@H]2C)(C)CC1
InChIKey: FRQMUZJSZHZSGN-HBNHAYAOSA-N
Synonyms: medroxyprogesterone, 520-85-4, Medroxyprogesteron, Medroxiprogesterona, Medroxyprogesteronum, Medrossiprogesterone, 17-Hydroxy-6alpha-methylprogesterone, 6alpha-Methyl-17alpha-hydroxyprogesterone, 17alpha-Hydroxy-6alpha-methylprogesterone, 6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione, Farlutal inyectable, 17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione, DTXSID0036508, HSU1C9YRES, U 8840, (6alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione, (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one, CHEBI:6715, DTXCID8016508, Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-, G03AC06, NSC27408, 17 alpha Hydroxy 6 alpha Methylprogesterone, 17 alpha-Hydroxy-6 alpha-Methylprogesterone, (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta(a)phenanthren-3-one, RefChem:55562, (6 alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione, G03DA02, L02AB02, 208-298-6, Methylhydroxyprogesterone, Medroxiprogesteronum, Medroxy Progesterone, MFCD00069474, Medroxyprogesterone (INN), Pregn-4-ene-3,20-dione, 17-hydroxy-6-alpha-methyl-, Medroxyprogesterone (Standard), MLS000069571, MLS001076098, 17-hydroxy-6alpha-methylpregn-4-ene-3,20-dione, SMR000058769, Medrossiprogesterone [DCIT], NSC 27408, Hydroxymethylprogesterone, Medroxyprogesteronum [INN-Latin], Medroxiprogesterona [INN-Spanish], MEDROXYPROGESTERONE [INN], Medroxyprogesterone [INN:BAN], 17-Hydroxy-6.alpha.-methylprogesterone, (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one, CAS-520-85-4, 17.alpha.-Hydroxy-6.alpha.-methylprogesterone, 6.alpha.-Methyl-17.alpha.-hydroxyprogesterone, HSDB 3114, 6-alpha-Methyl-17-alpha-hydroxyprogesterone, UNII-HSU1C9YRES, MLS002639162, EINECS 208-298-6, Farlutal inyectable (TN), 17alpha-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione, BRN 2510965, Medroxyprogesterone Acetate EP Impurity B, FRQMUZJSZHZSGN-HBNHAYAOSA-N, NCGC00183122-01, 17alpha-Hydroxy-6alpha-methylprogesterone;U8840, CPD000058769, Opera_ID_433, CHEMBL1390, SCHEMBL37494, 4-08-00-02211 (Beilstein Handbook Reference), MLS001424229, GTPL2879, orb1302146, orb3025368, MEDROXYPROGESTERONE [MI], HY-B0648R, 17-Hydroxy-6a-methylprogesterone, MEDROXYPROGESTERONE [HSDB], MSK8518, HMS2052A13, HMS2230B08, MEDROXYPROGESTERONE [VANDF], HY-B0648, Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6-alpha)-, MEDROXYPROGESTERONE [WHO-DD], MEDROXYPROGESTERONE [WHO-IP], Tox21_113401, EBC-04399, LMST02030176, MSK8518-100A, s3635, AKOS015961681, MSK8518-1000A, Tox21_113401_1, CCG-101111, FM32162, NC00361, MRF-0000022, 17-Hydroxy-6-methylprogesterone;U8840, NCGC00023064-04, NCGC00023064-05, AC-14528, MS-25295, ST082267, SY076012, CS-0694930, M3113, NS00009207, C07119, C75441, D08166, Pregn-4-ene-3, 17-hydroxy-6.alpha.-methyl-, F799493, Q416667, BRD-K99615199-001-18-5, MEDROXYPROGESTERONE ACETATE IMPURITY B [WHO-IP], Medroxyprogesterone Solution in Acetonitrile, 1000ug/mL, Medroxyprogesterone Solution in Acetonitrile, 100ug/mL, Medroxyprogesterone, VETRANAL(TM), analytical standard, Pregn-4-ene-3, 17-hydroxy-6-methyl-, (6.alpha.)-, Z1501485367, 17-HYDROXY-6.ALPHA.-METHYLPREGN-4-ENE-3,20-DIONE, MEDROXYPROGESTERONE ACETATE IMPURITY B [EP IMPURITY], (1S,8S,11S,15S,2R,10R,14R)-14-acetyl-14-hydroxy-2,8,15-trimethyl-5-oxotetracyc lo[8.7.0.0<2,7>.0<11,15>]heptadec-6-ene, (6S,8R,10R,13S,17R)-17-Acetyl-17-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one
Theoretical properties:
molecular_formula: C22H32O3
molecular_weight: 344.5 g/mol
exact_mass: 344.23514488 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 1
heavy_atom_count: 25
topological_polar_surface_area: 54.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Crystals from chloroform
color: Crystals from chloroform
melting_point: 214.5 °C
solubility: Solubility at 25 °C: in acetone 1 in 50; slightly soluble in ether and methanol; sol at 25 °C in dioxane: 1 in 60 /Medoxyprogesteron acetate/
Descriptions:
{"pubchem": "Medroxyprogesterone is a 3-oxo 4-steroid that is pregn-4-ene-3,20-dione substituted by an alpha-hydroxy group at position 17 and a methyl group at position 6. It has a role as a contraceptive drug, a synthetic oral contraceptive and a progestin. It is a tertiary alpha-hydroxy ketone, a 17alpha-hydroxy steroid, a 20-oxo steroid and a 3-oxo-Delta(4) steroid.", "chebi": "A 3-oxo \u0394<small><sup>4</small></sup>-steroid that is pregn-4-ene-3,20-dione substituted by an \u03b1-hydroxy group at position 17 and a methyl group at position 6.", "chembl": "Unnamed Compound is a small molecule listed in the ChEMBL database but has not progressed to an approved clinical phase.", "wikipedia": "Medroxyprogesterone acetate (MPA), also known as depot medroxyprogesterone acetate (DMPA) in injectable form and sold under the brand name Depo-Provera among others, is a hormonal medication of the progestin type. It is used as a method of birth control and as a part of menopausal hormone therapy. It is also used to treat endometriosis, abnormal uterine bleeding, paraphilia, and certain types of cancer. The medication is available both alone and in combination with an estrogen. It is taken by mouth, used under the tongue, or by injection into a muscle or fat.\nCommon side effects include menstrual disturbances such as absence of periods, abdominal pain, and headaches. More serious side effects include bone loss, blood clots, allergic reactions, and liver problems. Use is not recommended during pregnancy as it may harm the baby. MPA is an artificial progestogen, and as such activates the progesterone receptor, the biological target of progesterone. It also has androgenic activity and weak glucocorticoid activity. Due to its progestogenic activity, MPA decreases the body's release of gonadotropins and can suppress sex hormone levels. It works as a form of birth control by preventing ovulation.\nMPA was discovered in 1956 and was introduced for medical use in the United States in 1959. It is on the World Health Organization's List of Essential Medicines. MPA is the most widely used progestin in menopausal hormone therapy and in progestogen-only birth control. DMPA is approved for use as a form of long-acting birth control in more than 100 countries. In 2023, it was the 257th most commonly prescribed medication in the United States, with more than 1 million prescriptions."}